To assess the test-retest reliability of the polysomnography-multiple sleep latency test (PSG-MSLT) diagnostic classification and measures and to study the determinants of its variability in patients with narcolepsy type 1 (NT1) or with noncataplectic central disorders of hypersomnolence (NCHS): type 2 (NT2), idiopathic hypersomnia (IH), and unspecified hypersomnolence (unspecified excessive daytime sleepiness [UnsEDS]). Methods: PSG-MSLT in drug-free conditions was administered twice (median interval of 1.9 years) in 22 patients with NT1 (10 males, median age 31.2 years) and 75 patients with NCHS (32 males, median age 25.7 years). Results: At the first PSG-MSLT, patients with NCHS were classified as having NT2 (22.7%), IH (26.7%), or UnsEDS (50.6%). A positive PSG-MSLT was confirmed in 72.7% of NT1. The classification consistency at retesting was significantly lower for the NT2 (47.1%), IH (25.0%), and UnsEDS (42.1%) categories than NT1 (81.3%). The between-test mean sleep latency (MSL) variability was significantly different in NT1 and NCHS, with higher changes in NT2 and lower in NT1. A longer test-retest interval was associated with improved MSL and MSLT normalization. Between-test variations in SOREMP number were associated with changes in nocturnal REM sleep parameters and MSL. No association was found with the clinical decision to repeat the evaluation or the disease clinical course.
INTRODUCTION
Central disorders of hypersomnolence are rare and disabling sleep pathologies that include narcolepsy type 1 (NT1), type 2 (NT2), and idiopathic hypersomnia (IH).
1 NT1 is characterized by excessive daytime sleepiness (EDS) and cataplexy, frequently associated with hypnagogic hallucinations and sleep paralysis, and is defined by cerebrospinal fluid (CSF) hypocretin-1 (Hcrt-1)/orexin-A deficiency.
2 NT1 is usually easy to diagnose, because cataplexy is a pathognomonic symptom of the disease 3 and Hcrt-1 is a highly specific and sensitive diagnostic biomarker. Currently, CSF Hcrt-1 level below 110 pg/mL is the most accurate measurement to confirm NT1 diagnosis, especially in the case of doubtful cataplexy. In contrast, there is no pathognomonic symptom or biomarker for NT2 and IH. 4, 5 Neurochemical studies on the CSF levels of monoamine metabolites in noncataplectic central disorders of hypersomnolence (NCHS) remain inconclusive, and the CSF Hcrt-1 levels are consistently normal, as well as those of histamine and tele-methylhistamine, in most cases. 6, 7 A recent study found that CSF from patients with NCHS (mainly IH) acted as a positive allosteric modulator of GABA-A receptors; 8 however, the bioactive CSF component is still unknown and we could not replicate these results. 9 Therefore, NT2 and IH diagnoses are challenging and are based on the clinical history, polysomnography (PSG), and multiple sleep latency test (MSLT) results. 1, 10 The standardized MSLT procedure was established 30 years ago, with several revisions concerning its interpretation and cutoffs for the diagnosis of narcolepsy. [11] [12] [13] [14] No specific cutoff was established for IH, and similar mean sleep latency (MSL) thresholds are used for NT1, NT2, and IH. MSLT test-retest reliability has been evaluated in small samples of healthy subjects and in patients with narcolepsy, with high correlations found between MSL and number of sleep onset REM sleep periods (SOREMPs) in both populations, after a short between-test time interval. 15, 16 Conversely, a low repeatability (10%-20%) of positive MSLT results was found in a large sample from the population-based Wisconsin cohort study, with a four-year-interval between tests. 17 A recent clinical cohort study on 29 patients with NT2 or IH and 7 patients with unspecified EDS (MSL above 8 minutes) confirmed the poor test-retest MSLT reliability after four years, with a change in diagnosis in more than 50% of patients. 18 Considering the limited knowledge on MSLT reliability in clinical-based populations of patients with central disorders of hypersomnolence, we performed a retrospective study to assess the test-retest reliability of (1) the MSLT diagnostic classification, (2) the MSLT measures (MSL and number of SOREMPs), and (3) the variability determinants in patients with NT1, NT2, IH, and unspecified hypersomnolence complaint who underwent two MSLTs in drug-free conditions.
Statement of Significance
Although the multiple sleep latency test (MSLT) is the gold standard for diagnosing central disorders of hypersomnolence, we found a poor test-retest replication of MSLT results in patients with initial diagnosis of narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) compared with NT1. This lack of repeatability is associated with the variability of the MSLT measures at the second testing, whereas the clinical decision to repeat the MSLT and the disease course do not have any significant influence. Clinical features need to be reassessed and the MSLT needs to be repeated at regular intervals to confirm a stable hypersomnia and to identify homogeneous groups of patients with a sufficiently accurate diagnosis of NT2 or IH for the identification of potential NT2 and IH biomarkers that are currently missing.
1
CSF Hcrt-1 levels were measured in 13 patients (all <110 pg/ mL, including six with undetectable levels). All patients with NT1 were HLA DQB1*06:02-positive.
Evaluation
All patients underwent twice a full-night PSG recording followed the next day by the MSLT according to the standard guidelines, with a median between-test interval of 1.9 years (range: 0.02-11.9), with 1.6 years (range: 0.02-11.9) for the NCHS and 3.8 years (range: 0.1-7.7) for the NT1 group. All patients were drug-free for at least 2 weeks prior to each evaluation. Seventy-seven patients (65 NCHS and 12 NT1) were treatment-naïve at the first test and 29 (26 NCHS and 3 NT1) at both. The MSLT consisted of five scheduled naps separated by a 2-hour interval, between 9:00 am and 5:00 pm. Each time, patients had 20 minutes to fall asleep. If they did fall asleep, they were awakened after 15 minutes. All the MSLT were rescored by two authors (AD and RL). Sleep onset was determined by the first epoch of any stage of sleep according to the latest guidelines.
14 The MSL of the five naps was computed for each patient. A SOREMP was defined by the occurrence of REM sleep within 15 minutes of sleep onset during the MSLT and PSG recordings. PSG assessed total sleep time, sleep efficiency, REM sleep percentage and latency, microarousal index, AHI, and PLMS indexes.
Sex, age at EDS onset, and family history of EDS (first and second degree) were recorded at baseline. Age at MSLT, BMI, clinical assessment of depressive symptomatology, daytime sleepiness quantified with the ESS and presence of cataplexy, hypnagogic/hypnopompic hallucinations, and sleep paralysis were recorded at both sleep evaluations. Based on medical charts, we classified the decision to repeat the sleep study in four categories: (1) systematic reassessment (including re-evaluation for a research protocol, for a new treatment, post-pregnancy), (2) uncertain diagnosis at baseline, (3) spontaneous clinical improvement, or (4) clinical aggravation. We also reported the physician's clinical judgment on sleepiness severity variations (improvement, stability, or worsening) at the second evaluation.
According to the ICSD-3 criteria, the PSG (SOREMP) and MSLT results (MSL and SOREMP number) classified patients as follows: (1) 
Statistical Analysis
Demographic characteristics and clinical data were described using percentages or frequencies for categorical variables and medians with ranges [minimal and maximal values] for continuous variables. Distributions were mostly skewed, according to the Shapiro-Wilk's test. To compare categorical variables between groups, the chi square or Fisher's exact test was used. The Mann-Whitney and Kruskall-Wallis tests were employed to compare continuous variables with two and three groups or more, respectively. When a significant relationship was found between more than two groups, two-by-two comparisons were performed to determine whether groups within the study were significantly different. A correction for multiple comparisons with the Bonferroni method was then used. A change of continuous variables between two MSLTs was defined as the difference between the second and first assessment. The Wilcoxon signed-rank test was run to compare differences of continuous variables between assessments. Statistical significance was set at p < .05. Statistical analyses were performed using SAS, version 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Patients' Baseline Characteristics, First PSG-MSLT Results, and Diagnostic Classification At first assessment, among 75 patients with NCHS, 17 (22.7%) filled the PSG-MSLT diagnostic criteria for NT2, 20 (26.7%) for IH, 22 (29.3%) for REM dysregulation, and 16 (21.3%) had normal MSLT results despite their EDS complaint. We grouped the patients with REM dysregulation and normal results (total n = 38) in the "unspecified EDS" (UnsEDS) category. Twenty patients (9 with IH and 11 with UnsEDS) also performed a 24-hour continuous PSG. Seven patients with IH and nine with UnsEDS had a total sleep time higher than 11/24 hours (data not shown).
Among 22 patients with NT1, 16 (72.7%) were classified as having narcolepsy based on the PSG-MSLT criteria ("positive PSG-MSLT," hereafter). Among six others, five had ≥2 SOREMPs but MSL > 8 minutes, and the other one had MSL > 8 minutes and only one PSG SOREMP; however, all six had clear-cut cataplexy and five had a lumbar puncture that confirmed Hcrt-1 deficiency (<110 pg/mL).
The demographic, clinical, and neurophysiological characteristics according to the diagnosis at first assessment (NT1, NT2, IH, and UnsEDS) are shown in Table 1 . Age was significantly different among groups; however, post hoc comparisons indicated that age was significantly lower only in the UnsEDS group compared with the NT1 group. As expected, patients with NT1 had lower CSF Hcrt-1 levels and were more frequently HLA DQB1*06:02-positive than the other groups. Patients with NT1 also had higher ESS scores and microarousal index value and reported more frequently sleep paralysis than patients with UnsEDS. Similarly, patients with NT1 reported more frequently hypnagogic hallucinations and had a shorter REM sleep latency than the other groups, and less sleep efficiency than the IH and UnsEDS groups.
Test-Retest Reliability of the PSG-MSLT Diagnostic Classification
At the second MSLT evaluation, among patients with NCHS, 14 (18.7%) filled the PSG-MSLT criteria for NT2, 19 (25.3%) for IH, 9 (12.0%) for REM dysregulation, and 33 (44.0%) had normal MSLT results ( Table 2) . None of them developed cataplexy during the between-test time interval. Only 8 of 17 patients (47.1%) who were initially classified as having NT2 remained in this diagnostic group at the second evaluation, whereas eight were classified as normal and one as having REM dysregulation. Only 5 of 20 patients (25.0%) with an initial diagnosis of IH remained in this diagnostic category, whereas five were reclassified as having NT2, one REM dysregulation and nine a normal phenotype. Seven of 22 patients (31.8%) with REM dysregulation remained in this group at retesting, whereas five were classified as having NT2, three IH, and seven a normal phenotype. Finally, among 16 patients (56.2%) with normal phenotype, nine remained in this group at retesting, whereas six were classified as having IH and one as having NT2. Among 16 patients with NT1 and baseline positive MSLT, 13 (81.3%) remained in the narcolepsy group at the second evaluation, whereas two were classified as having REM dysregulation and one hypersomnia phenotype ( Table 3) .
The repeatability of the PSG-MSLT diagnostic classification in the NT1 group (81.3%) was significantly higher than in the NT2 (47.1%, p = .04), IH (25.0%, p = .008), both NT2 and IH (35.1%, p = .002), and UnsEDS groups (42.1%, p = .008), as well as when compared with all patients with NCHS (38.7%, p = .002).
The inclusion or not of the nocturnal SOREM in the total number of SOREMPs (e.g., ICSD-2 criteria) did not significantly change the baseline and re-testing classifications. Similarly, taking into consideration only the daytime SOREMPs did not change the baseline and retesting diagnostic classifications, because the frequency of nocturnal SOREMPs was low in patients with NCHS (five patients at baseline and seven at the second evaluation). By applying these criteria, only one patient with NT2 was classified as having IH at both evaluations, whereas it did not affect the number of patients with NT1 with positive MSLT.
Test-Retest Reliability of the 8-minute MSL Cutoff
Among 37 patients with NCHS and a pathological MSL (≤8 minutes) at the first assessment, a MSL ≤ 8 minutes was confirmed in 18 
MSL Value Variability Between Tests
Overall, MSL values were significantly different among diagnostic groups at both assessments (p < .0001 at the first assessment and p = .004 at the second assessment). The median MSL value was lower in patients with NT1 than in those with NCHS both at the first (NT1: 5. We then classified patients with NCHS in three subgroups according to the tertiles of MSL changes between MSLTs (Table 4) 
SOREMP Number Variability Between Tests
At the first assessment, 39 (52.0%) patients with NCHS had ≥2 SOREMPs and 28 (37.3%) at the second assessment. Compared with patients with ≥2 SOREMP only at the first assessment (n = 18), those with ≥2 SOREMPs at both evaluations (n = 21) were more often males (66.7% vs 33.3%; p = .04), with shorter REM sleep latency (−14.0 minutes vs +8.0 minutes; p = .04) and MSL (−0.8 minutes vs +3.9 minutes; p = .02) at the second evaluation. The test-retest interval was longer in the group with <2 SOREMPs than in patients with ≥2 SOREMPs at the second evaluation (2.8 years vs 0.7; p = .004). Among 36 patients with NCHS and <2 SOREMPs at baseline, only seven had ≥2 SOREMPs at retesting. The PSG REM sleep latency was reduced (−40.0 minutes vs +5.0 minutes; p = .003) and the REM sleep percentage increased (+6.7% vs −1.4%; p = .002) in patients with ≥2 SOREMP at the second evaluation.
Effect of the Clinical Decision to Repeat the PSG-MSLT Evaluation
Sleepiness severity improved in 14.9% (six NT2, two IH, and three UnsEDS), worsened in 8.1% (one NT2, three IH, and two UnsEDS), and remained stable in 77.0% of patients with NCHS, according to the physician's clinical impression of change at the second evaluation. The second PSG-MSLT recording was decided for a systematic reassessment (n = 26), because of uncertain baseline diagnosis (n = 38) or due to clinically significant changes in the symptom severity (n = 11). Demographic, clinical, and neurophysiological characteristics were not significantly different in these three groups, but for a longer test-retest interval in patients with a systematic reassessment.
DISCUSSION
We examined the test-retest reliability of the MSLT (median between-test time interval of 1.9 years) in two well-characterized clinical populations of patients with NT1 and NCHS. Our findings highlight the lack of stability of the PSG-MSLT based-classification in NCHS, but not in NT1, with frequent diagnostic changes in the NT2 and IH groups. The MSL and SOREMP variability showed high interindividual heterogeneity that was associated with the time interval between tests, but not with the spontaneous course of the clinical symptoms. As a positive control group, we included 22 patients with NT1 who had clear-cut cataplexy, carried the HLA DQB1*06:02 allele, and had low CSF Hcrt-1 levels (available for 13 patients). At the first test, 27.3% of patients with NT1 had a MSL > 8 minutes and/or <2 SOREMPs (i.e., negative MSLT). A lower rate (6.6%) of false negative MSLT results was recently reported in NT1. 19 This discrepancy could be explained by the clinical setting of our study, in which most patients had a second MSLT evaluation due to a specific reason, including nonconclusive baseline findings. On the other hand, in our study, the test-retest reliability for NT1 was high (83.1% of patients had a positive MSLT at both evaluations). Similarly, in a previous study, 28/30 narcoleptic patients (83% with cataplexy) had positive MSLT results at both evaluations within a median interval of 4.8 years.
16 NT1 is a life-long disease, without spontaneous remission, but with highly heterogeneous disease course, Hcrt-1 levels, and MSLT results. 20 The MSLT results are generally robust, except in elderly patients in whom MSL increases and the number of SOREMPs decreases progressively. 21 Although an age effect cannot be formally ruled out in our study, the test-retest MSLT variability in NT1 mainly reflects the test intrinsic performances without any effect of the spontaneous disease course.
In the NCHS population and differently from that observed in the NT1 group, we confirmed previous preliminary findings on the poor reliability of the MSLT based-diagnoses of NT2 and IH. During an interval of almost 2 years, the diagnosis changed in more than 50% of patients who were initially classified as having NT2. None of the patients with initial NCHS criteria developed cataplexy between the MSLT1 and MSLT2. Trotti et al. found similar rates of diagnostic instability (only 5 of 15 patients in the NT2 category had similar MSLT results at follow-up). 18 Another study reported that fewer than half of 18 patients with NT2 had a positive MSLT at both assessments. 19 The reliability of the MSLT-based narcolepsy criteria has also been studied in the general population (823 subjects had two PSG-MSLT at a 4-year interval). 17 Among subjects without shift-work and with habitual nighttime sleep duration >6 hours, the stability of a positive MSLT was very low (10%-20%). A large general population-based cohort showed a high rate of subjects with EDS and positive MSLT (4.1% of men and 0.4% of women) with a strong association with shift work, sleep deprivation, and antidepressant intake. 22 Another study confirmed the frequent number of SOREMPs in the general population, especially in those with short MSL, with significant association with shift work and sleep apnea. 23 Altogether, these results confirm the limited contribution of a single PSG-MSLT assessment for the diagnosis of NT2. 24 Indeed, NT2 is a diagnosis of elimination and only a minority of patients have a stable phenotype with daytime hypersomnolence and high REM sleep propensity, as measured by the MSLT. To establish a genuine diagnosis of NT2, we recommend to reassess the clinical features and to repeat the MSLT (after exclusion of shift work, sleep deprivation, and antidepressant intake) to identify patients with positive MSLT at both evaluations.
Similarly, we found extremely low test-retest stability for the MSLT-based diagnosis of IH. Only 25% of patients with initial criteria for IH were classified as having IH at the second test. This is lower than in a previous study where 8 of 14 patients with IH had stable MSLT results/diagnostic classification. 18 MSLT contribution to the diagnosis of IH seems, thus, to be limited in most patients, and other features of hypersomnolence should also be taken into account for the diagnosis of this NCHS subtype with long sleep time.
The low test-retest MSLT repeatability in NCHS could be explained by the intrinsic features of the test, but also by the spontaneous clinical course of such disorders. Until recently, IH and NT2 were considered as long-lasting diseases; however, several case series reported spontaneous improvement or remissions in 11%-25% of patients with IH. [25] [26] [27] [28] Our results are in line with these observations because 14.9% of patients with NCHS had a spontaneous clinical improvement after a median of 1.6 years. A higher rate of remission was recently reported in patients with NCHS after a 5-year follow-up (32.5% in IH and 44.6% in NT2). 29 Our study also shows that the sleepiness improvement, based on the ESS score or the physician's clinical impression, was not associated with MSLT normalization in patients with pathological baseline MSL. This discrepancy between subjective and objective daytime sleepiness changes in NT2 and IH has been already described in hypersomnia associated with major depression. 30, 31 We found here a strong effect of the test-retest interval (80% of normalization of the MSL after 4 years), suggesting that objective daytime sleepiness tends to decrease over time in both NT2 and IH. Interestingly, the duration of the between-test interval was not associated with a pathological MSL at the second assessment in patients with normal MSL at first-assessment.
Two factors contributed to the variability of MSLT-based classifications: sleepiness (i.e., MSL) and the REM sleep propensity (i.e., daytime and nocturnal SOREMPs). We found significant between-test changes in the MSL values, with a large heterogeneity among patients, and also in the total number of SOREMPs. Indeed, the SOREMP number remained stable only in 50 patients at both evaluations (21/75: ≥2 SOREMPs; 29/75: <2 SOREMPs). Moreover, the changes in SOREMP number were associated with variations in the nocturnal REM sleep parameters (i.e., REM sleep latency and REM sleep percentage). The number of SOREMP was also associated with MSL and with sex (male), as previously described in the general population. 22, 23 Several limitations should be taken into consideration when interpreting our results. First, short sleep duration and sleep deprivation have major effect on the MSLT results. Accordingly, we included patients with a reported main sleep period of at least 7 hours, but this was not objectively assessed by actigraphy. 4 Second, overall, only 29 patients were treatment-naïve at both evaluations, whereas the others stopped their stimulant (for patients with NT1 and NHCS) or antidepressant medication (only for patients with NT1) at least 2 weeks before each test. An acute withdrawal effect cannot be totally excluded, although 2 weeks correspond to more than eight half-lives of psychostimulant medications. Third, our clinical population sample was well characterized, but relatively small. Moreover, all patients were referred to a single reference national sleep clinic. We did not use a controlled prospective design to systematically reassess patients; the interval between the test-retest assessments was variable and the decision to repeat the PSG-MSLT not random. The retrospective design could have introduced a bias that might have increased the high test-retest variability of PSG-MSLT results and the unexpected high rate of negative MSLT in the NT1 group. Fourth, HLA typing and CSF Hcrt-1 levels were not available for all participants, with none of the patients being systematically reassessed for Hcrt-1 levels. We did not include children below 16 years of age with central disorders of hypersomnolence to avoid additional bias regarding the age effect on the MSLT results. 21 Finally, due to the retrospective nature of our observational study with a heterogeneous design, our findings need to be confirmed in another prospective study.
In conclusion, the PSG-MSLT measures and diagnostic classification lack stability in central disorders of hypersomnolence, with frequent diagnostic changes for NT2 and IH, in contrast to NT1. Our results challenge the validity of the established MSL cutoff for the diagnosis of NT2 and IH. On the basis of these findings, we highlight the need to reassess the clinical features and to repeat the MSLT at regular intervals to confirm a stable hypersomnia and to provide a sufficiently accurate diagnosis of NT2 and IH. Repeated testing may allow the identification of 
